Whalesbook
Samsrita Labs Limited has announced it will close its trading window starting April 1, 2026. The window will remain shut for 48 hours after the company releases its audited financial results for the fourth quarter and the full fiscal year ending March 31, 2026.
These closures are a standard practice designed to prevent insider trading. By restricting company insiders from trading securities when price-sensitive information, such as financial results, has not yet been publicly disclosed, Samsrita Labs aims to maintain market integrity and ensure a level playing field for all investors.
Samsrita Labs, which manufactures Active Pharmaceutical Ingredients (APIs) and is listed on the NSE, regularly follows this procedure around its financial reporting periods. This practice reinforces its commitment to adhering to SEBI guidelines.
During this period, designated employees and their close relatives, including key management, are prohibited from trading the company's shares. The duration of the closure is directly linked to the announcement of the Q4 FY26 financial results, meaning investors will need to wait for the official release before any trading activities involving insiders can resume.
Risk of Extended Closure: Any delays in announcing the audited financial results for Q4 FY26 will directly prolong the trading window closure period.
Other Indian pharmaceutical companies, especially those in the API sector such as Granules India and Laurus Labs, also routinely implement similar trading window closures around their financial results announcements to comply with SEBI regulations.
Investors will be looking for the exact date and time of the company's audited Q4 FY26 financial results announcement and the subsequent reopening of the trading window. Any guidance or commentary accompanying the results will also be key.